GLP-1 Cost and Access Guides
Wegovy costs $1,350/month without help. Most patients pay far less. Every access pathway — insurance coverage, manufacturer savings programmes, compounded alternatives, and prior authorisation appeals — explained.
What will a GLP-1 actually cost you? →
Pick your medication and coverage to see your real monthly & annual out-of-pocket across every legitimate route, ranked cheapest first.
The GLP-1 Price Index →
Track the median monthly cash price of GLP-1s over time — compounded vs brand, semaglutide vs tirzepatide, rebased to 100. Free to cite, embed, and download.
Does your state’s Medicaid cover GLP-1s for obesity? →
A state-by-state map of Medicaid coverage for obesity GLP-1s, verified against KFF and state Medicaid sources. Only 13 states cover them.
Will your insurance cover a GLP-1? →
A decision tree for commercial, Medicare, and Medicaid-by-state coverage — the likely answer for your situation, the exact next step, and a free coverage kit (appeal letter + prior-authorisation checklist).
Compounded vs brand: your 12-month cost →
If the compounding crackdown moves you onto brand-name Wegovy or Zepbound, see what it does to a full year of out-of-pocket cost — projected from live US prices.
GLP-1 discounts & coupons: every way to pay less →
Paying out of pocket? Every US channel compared — manufacturer savings cards, LillyDirect/NovoCare self-pay, GoodRx, Costco, and compounded telehealth — dated and sourced. Free to cite, embed, and download.
Find your cheapest GLP-1 channel →
Tell us your insurance and your drug; we’ll rank the cheapest US ways to pay for your exact situation — cards, self-pay, coupons, and compounded.
Cash-pay costs
Wegovy Cost Without Insurance: Cash-Pay, NovoCare, Savings Cards, and the May 2026 Price Map
Wegovy cash pay through NovoCare Pharmacy is $349 a month in May 2026 for the injection, with a $199 introductory rate for the two lowest doses. The oral Wegovy pill starts at $149 a month. Here is what each access route actually costs and who qualifies.
Zepbound Cost: LillyDirect, Insurance, and the Cash-Pay Tier (May 2026)
Eli Lilly cut LillyDirect vial prices in December 2025 and extended the same tier to the KwikPen in February 2026. The cash-pay map for Zepbound now runs $299–$449 a month, with employer-plan and Medicare paths that look very different from a year ago.
Cheapest Place to Get Wegovy in 2026: Every Legitimate Path Ranked by Out-of-Pocket Cost
From NovoCare's $199 intro rate to the new $50 Medicare bridge, here is every legitimate 2026 route to Wegovy ranked by what you actually pay.
Tirzepatide Cash Price in 2026: LillyDirect, Compounded, and Insurance Paths
Tirzepatide list price is $1,069–$1,086/month. Cash-pay patients can access it for $299–$449/month through LillyDirect. Here is the full, dated price map.
Cheapest Ways to Get GLP-1 Drugs: Every Access Pathway Ranked by Cost
Wegovy costs $1,350/month without insurance. But there are at least six pathways to GLP-1 therapy at substantially lower cost — from manufacturer savings programmes to compounded versions, international pharmacies, and clinical trials. Here is every option ranked.
Manufacturer programmes
NovoCare Wegovy Enrollment: Step-by-Step Walkthrough (May 2026)
NovoCare is Novo Nordisk's direct cash-pay program for Wegovy. It costs $349/month flat, skips insurance billing entirely, and enrollment takes about 15 minutes. Here is the step-by-step walkthrough as of May 2026.
LillyDirect Zepbound Enrollment: Step-by-Step Walkthrough (May 2026)
LillyDirect is Eli Lilly's direct cash-pay program for Zepbound. As of May 2026, the Self Pay tier runs $299–$449/month depending on dose — same price for the vial and the KwikPen. Here is the full enrollment walkthrough.
GLP-1 Savings Cards: Wegovy, Zepbound, Mounjaro, and Ozempic (2026 Guide)
Manufacturer copay cards can cut your GLP-1 bill to $25 a month — if you qualify. Here is every card compared, how to activate each one, and the pitfalls that catch patients off guard.
Insurance and access
How to Get a GLP-1 Prescription: The Complete Guide to Access Pathways
GLP-1 drugs require a prescription. There are three main access pathways — your primary care doctor, a specialist, or a telehealth provider — each with different speed, cost, and monitoring requirements. Here is how each pathway works and what to expect.
GLP-1 Prior Authorization Denied? How to Appeal (Step-by-Step)
A denial is not a final answer. Here is the complete process for appealing a GLP-1 prior authorization denial — from reading the denial letter to requesting an external review — with the documentation that actually moves insurers.
Step Therapy for Wegovy and Zepbound: How It Works and How to Get Through It
Most insurance plans that cover GLP-1s for obesity require step therapy — proving you tried cheaper drugs first. Here is what the standard requirements look like and how to build a documentation record that supports approval.
GLP-1 Insurance Coverage Guide 2026: Commercial, Medicare, and Medicaid
GLP-1 coverage depends on what the drug is approved for (T2D vs obesity), who pays (commercial insurer, Medicare, Medicaid), and whether your employer's plan has opted in. Here is the current coverage map.
Does Medicaid Cover GLP-1 Drugs for Weight Loss? A State-by-State Reality Check
Medicaid GLP-1 coverage for obesity is patchwork: about 13 states cover Wegovy or Zepbound; most do not. T2D patients have better coverage. Here is the real picture and your options if your state doesn't cover it.
Medicare and GLP-1s in 2026: What’s Covered, What’s Not, and the Bridge Program
Starting July 1, 2026, Medicare's GLP-1 Bridge offers eligible Part D enrollees Zepbound KwikPen and Wegovy for $50/month. Here's exactly who qualifies, what's excluded, and what happens when the Bridge closes.
What to Do When Your GLP-1 Drug Is Out of Stock or Backordered
GLP-1 drug supply has been volatile since 2022. Even as Novo Nordisk and Eli Lilly have expanded manufacturing, specific doses and pen formats are periodically unavailable at individual pharmacies. Here is a practical guide for patients who cannot fill their prescription.